[1] Yamada M, Yamamoto Y, Sugiura T, et al. Comparison of the clinicopathological features in small bile duct and bile ductular type intrahepatic cholangiocarcinoma. Anticancer Res, 2019, 39(4):2121-2127. [2]朱明辉, 张先舟, 韩风, 等. 腹腔淋巴结清扫范围对肝内胆管细胞癌患者根治性切除术预后的影响. 中华肝胆外科杂志, 2020, 26(1):48-52. [3] Lee J, Kim SH, Kang TW, et al. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology, 2016, 281(1):119-128. [4] Choi SH, Lee SS, Kim SY, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: cifferentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology, 2016, 282(3):771-781. [5] Hulshoff JB, Mul VEM, De Boer HEM, et al. Impact of endoscopic ultrasonography on 18F-FDG-PET/CT upfront towards patient specific esophageal cancer treatment. Ann Surg Oncol, 2017, 24(7):1828-1834. [6] Teoh EJ, Mcgowan DR, Bradley KM, et al.18F-FDG PET/CT assessment of histopathologically confirmed mediastinal lymph nodes in non-small cell lung cancer using a penalised likelihood reconstruction. Eur Radiol, 2016, 26(11):4098-4106. [7] Groheux D, Cochet A, Humbert O, et al.18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med, 2016, 57(1):17-26. [8] Choi BI, Lee JM, Han JK. Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging, 2004, 29(5):548-557. [9] Miura F, Okazumi S, Takayama W, et al. Evaluation of CT during arterial portography for preoperative diagnosis of intrahepatic cholangiocarcinoma. Hepatogastroenterology, 2006, 53(69):435-437. [10] 戴伟, 钱叶本. Bismuth-CorletteⅢ型肝门部胆管癌治疗策略. 中华普通外科杂志, 2019, 34(1):14-17. [11] Higashi M, Yonezawa S, Ho JJL, et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology, 2010, 30(6):1347-1355. [12] Terada T, Nakanuma Y. Expression of tenascin, type IV collagen and laminin during human intrahepatic bile duct development and in intrahepatic cholangiocarcinoma. Histopathology, 1994, 25(2):143-150. [13] Li J, Kuehl H, Grabellus F, et al. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol, 2010, 98(6):438-443. [14] Ma K, Cheung T, She W, et al. Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer. World J Surg, 2018, 42(3):823-834. [15] Mahmood, Maryam. In response to letter regarding "meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis". J Nucl Cardiol, 2018, 26(3):941-943. [16] 程远, 王振光, 杨光杰, 等. 18F-FDG PET/CT孤立性肺结节恶性风险预测模型的建立和效能评价. 中华核医学与分子影像杂志, 2019, 39(3):129-132. [17] Wang TA, Xian SL, Guo XY, et al. Combined18F-FDGPET/CT imaging and a gastric orthotopic xenograft model in nude mice are used to evaluate the efficacy of glycolysis-targeted therapy. Oncol Rep, 2018, 39(1):271-279. [18] Kang KJ, Ahn KS, Kim YH, et al. SAT-394-genetic features associated with18F-FDG uptake in intrahepatic cholangiocarcinoma. J Hepatol, 2019, 70(1):806-807. [19] 李小萌, 吴宁, 粱颖, 等.18F-FDG PET/CT与食管癌治疗前分期的相关性研究. 中华核医学与分子影像杂志, 2015, 35(2):88-91. [20] 杨晖, 关志伟, 富丽萍, 等.18F—FDGPET/CT在肝外胆管细胞癌术前诊断和分期中的价值. 中华核医学与分子影像杂志, 2017, 37(2):65-69. |